Johnson & Johnson posted a loss in the first three months of the year as it booked a massive $6.9 billion charge related to its recently-agreed proposal to settle clai
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<